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ACCEPTED MANUSCRIPT 6 higher expression of the gene, which was associated with worse response and increased risk for relapse [22] . These retrospective and single-center studies have provided intriguing evidence for a significant pharmacogenomics contribution to therapeutic efficacy, although some of these results remain controversial and require confirmation through prospective clinical trials.
Chen et al. studied more than 500,000 SNPs in 485 children with ALL. Five SNPs with an identical relationship to different alleles of the glutamate α-amino-3-hydroxy-5-methyl-4-isocazolepropionic acid (AMPA) receptor subunit 1 gene (GRIA1) were associated with hypersensitivity to asparaginase [23] . GRIA1 gene encodes a subunit of glutamate receptor 1, which is a predominant excitatory neurotransmitter receptor in the brain. In addition, glutamate has recently been recognized as an immune modulator [24] .
Furthermore, recent report demonstrated an association between HLA-DRB1*0701 with asparaginase allergy due to amino acid variants within the binding pocket of HLA-DRB1 that conferred higher binding affinity [25] . Highlighting the potential importance of such genetic variability to predict adverse drug effect the Food and Drug Administration (FDA) recently approved testing for HLA-B*5701 prior to the administration of abacavir, to patients with human immunodeficiency virus (HIV) as a mean of avoiding drug toxicity [26, 27] . Identification of genetic polymorphisms which predict drug toxicity provides a new paradigm for the incorporation of
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7 pharmacogenetics into routine clinical practice, although additional prospective evidence proving these associations may be required.
Glucocorticoids
Glucocorticoids are the keystone of ALL therapy. They exert their activity by reducing cell proliferation and promoting apoptosis or cell arrest by binding to intracytoplasmic glucocorticoid receptors. In tumor cells, up-regulation of P-glycoprotein, encoded by the ATP-binding cassette sub-family B1 (ABCB1) gene, is responsible for glucocorticoid resistance. C3435T [28] , G2677T/A [29] and T129C [30] have been identified as polymorphisms associated with possible glucocorticoid resistance based on in vitro studies. Better responses to glucocorticoids therapies have been observed in patients with the A1082G SNP in the promoter region of the interleukin-10 (IL-10) gene [31] . The SNP results in up-regulated IL-10 expression and increases the binding of glucocorticoids to monocytes. Likewise, deletion of the glutathione-S-transferase (GSTs) type M1 gene has been associated with initial responsiveness to glucocorticoids as well as the severity of infectious complication by decreasing glucocorticoid metabolism [32, 33] . In B-cell ALL, Pottier et al. showed that mutations in three subunits of the nucleosome-remodeling complex correlate with in vitro glucocorticoid resistance using a panel of 177 primary pediatric ALL samples [34] . Further, Real et al. demonstrated that the NOTCH pathway is a pivotal determinant of glucocorticoid sensitivity in T-cell ALL. Combination therapy with a gamma-secretase inhibitor (inhibitor of NOTCH1) and glucocorticoids could restore
the anti-leukemic effect of glucocorticoids in glucocorticoid-resistant T-cell ALL [35] .
In addition, gene expression profiles of carbohydrate metabolism have revealed that increased glucose metabolism can induce prednisolone resistance [36] . Inhibition of molecules in the glycolytic pathway, for example glyceraldehydes-3-phosphate dehydrogenase (GAPDH) and 2-deoxy-D-glucose (2-DG), reverse glucocorticoid resistance in both cell lines and primary ALL samples [36] . Similarly, overexpression of the X-linked inhibition of apoptosis protein (XIAP) has been shown to predict chemotherapy resistance. In childhood with T-cell ALL, poor prednisone response was associated with increased XIAP expression, and glucocorticoid resistance could be reversed by XIAP inhibition [37] . polymorphisms may impact the risk of bone mineral density loss in a study of 309 long-term ALL survivors [41] . A total of 10-15% of children develop AVN after receiving ALL treatment, and this complication can be directly attributable to the prolonged use of high-dose glucocorticoids [42, 43] . A previous case report suggested variants of thymidylate synthase (TYMS) were associated with a higher risk for developing AVN [44] ; however, these results were not confirmed in subsequent studies [45] . Instead, prospective evaluation identified a SNP of plasminogen activator inhibitor-1 (PAI-1) as a candidate for the prediction of osteonecrosis [45] .
Genome-wide association studies unraveled polymorphisms of acid phosphatase 1 (ACP1), which regulates lipid levels and osteoblast differentiation, as a potential predictor of osteonecrosis risk [46] . Three genes (alpha-2-HS-glycoprotein, IL-6, polymerase delta interacting protein 3) were significantly associated with dexamethasone-induced sleep disturbance [47] . In summary, it is clear that the adverse effects of glucocorticoids are linked to differential rates of clearance mediated by population variant as well as interaction with other cytokines. Prospective validation for the predictive value of such SNPs may in the future allow better prediction of severe side effects from glucocorticoids.
6-Mercaptopurine (6-MP)
6-MP is an antimetabolite used for more than 40 years. Combined with weekly MTX,
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10 daily 6-MP is the backbone of maintenance therapy for ALL, with or without pulses of vincristine and dexamethasone. After being metabolized to 6-thioguanine nucleotides (6-TG), it inhibits de-novo purine synthesis. Bhatia et al. reported that absolute 6-MP or 6-TG levels were not helpful for prognosticating relapse risk in a study including 744 pediatric patients who had achieved remission. Instead, high intra-individual variability in 6-TG levels contributed to relapse risk in this population, which reinforce the need to minimize the fluctuation of 6-MP [48] .
The enzyme, thiopurine methyltransferase (TPMT) catalyzes the S-methylation of thiopurine to an inactive metabolite. These genes are co-dominantly inherited, containing nonsynonymous SNPs, leading to significant differences in enzyme activity and important clinical consequences [49] . Patients with TPMT SNPs associated with lower enzymatic activity, either heterozygous or homozygous can cause moderate to severe myelosuppression when treated with conventional doses of 6-MP [50] . Similarly, homozygosity for the TPMT deficient SNP can result in greater risk for radiation-induced brain tumors and chemotherapy-induced acute myeloid leukemia [51] , although these patients tend to have a lower rate of relapse rate [52] .
Since 3-14% of patients are heterozygous for TPMT associated with lower enzyme activity, routine pre-treatment testing is suggested and once identified, these patients should start with a dose reduction in the 6-MP level by 30-70% [53] . Notably, the FDA now recommends testing for the most commonly identified inactive SNP genotype, which can prospectively predict patients at higher risk of developing
6-MP-induced hematopoietic toxicity [16, 49, 50] . It is most useful in ALL protocols containing high doses 6-MP (>50 mg/m 2 /day) [5] . Caucasians, leading to a higher risk for 6-MP induced toxicity [58, 59] . Therefore, identification of variant ITPA SNPs may be the next pharmacogenomics test adopted into clinical practice.
Methotrexate (MTX)
MTX is a folate inhibitor introduced into clinical practice in the 1950s and remains a A C C E P T E D M A N U S C R I P T [61] . Impaired function of this transporter has been recognized as a major mechanisms for MTX resistance [62] . A common variant of RFC-1, G80A is associated with decreased inward MTX transportation [63] .
Furthermore, Laverdiere et al. demonstrated that pediatric ALL patients with the
G80A variant of RFC-1 had worse prognosis manifested by increased relapse rate and decreased EFS, than those carrying the GG genotype [64] . In contrast with these results, other studies failed to reveal a relationship between disease outcome and RFC-1 polymorphisms. These data may be explained by differences in the doses of MTX used in the two studies. At higher dose (5 g/m 2 body surface area), MTX can enter cells via passive diffusion, and thus polymorphisms resulting in decreased transporter mediated influx may be less significant [65, 66] . clearance [70] . Therefore, SLCO1B1 SNPs are significant determinants for MTX toxicity, especially stomatitis and mucositis during consolidation therapy.
Methylenetetrahydrofolate reductase (MTHFR) is the most extensively studied gene in MTX metabolism. It catalyzes the conversion of 5,10-methylene-tetrahydrofolate to 5-methyl-tetrahydrofolate, which serves as a methyl donor to convert homocysteine to methionine [71] . Two SNPs, C677T (rs1901133) resulting in substitution of alanine with valine at codon 222 (Ala222Val) [72] and A1298C (rs1801131) resulting in substitution of alanine for glutamic acid at codon 429 (Glu429Ala) [73] have been related to reduced activity of MTHFR and increased MTX level. Some case reports demonstrated that the C677T (rs1901133) variant induced neurotoxicity [74] and liver toxicity [75] , whereas, other publications failed to confirm this relationship [76, 77] . A study that recruited 520 children with ALL demonstrated that the C677T variant allele was significantly associated with relapse without increased risk of toxicity or showed that individuals who were homozygous for triple repeats (3R) had worse outcome when compared with children with other genotypes [79] . A subsequent study
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extended to 259 children with ALL confirmed the finding that 3R increased the risk of relapse and fatal outcome [80] . ABCB1, ABCC2 and ABCC4 genes, leading to increased MTX levels and toxicity [83] .
Presence of the SNP of rs639174 in DROSHA gene, which encodes the enzyme RNAse III processing miRNA, was related to gastrointestinal toxicity induced by MTX in pediatric B-cell ALL patients. This study was the first to demonstrate a potential role for polymorphisms in miRNA processing genes to predict for toxicity in ALL management [84] . Further studies of miRNA, epigenetics and genome-wide
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16 screening will better elucidate the individual variability in MTX efficacy and toxicity.
Vincristine
Vincristine binds to tubulin dimers, interfering with microtubule formation and thereby mitotic spindle dynamics, and resulting in mitotic arrest and leukemic cell death in metaphase. Vincristine-induced neurotoxicity, characterized by constipation and motorsensory dysfunction remains a serious and largely unpredictable problem for patients with ALL. The cytochrome P450 enzyme (CYP) 3A5 is responsible for 55-59% of total vincristine metabolism [85] . An early study revealing variable grades of neurotoxicity between Caucasians (34.8%) and African-Americans (4.8%)
suggested a role for polymorphisms in CYP3A5 in vincristine-induced toxicities [86] .
Another study involving 616 pediatric ALL patients did not find an association between EFS and CYP3A5 polymorphisms in ALL patients [87] . However, a sub-group evaluation from this study demonstrated that in T-cell ALL patients the CYP3A5*36986A>G allele, which leads to low expression of CYP3A5, had an eight times higher relapse rate, indicating a specific role for CYP3A5 in T-cell ALL [87] . In pre-B ALL, expression of CYP3A5 was associated with less vincristine-induced peripheral neuropathy compared to non-expressors [88] . This effect may be achieved by a lower ratio of vincristine to its' primary metabolite (M1) [88] . Despite these intriguing results, two other studies, which enrolled a total of 86 patients, and evaluated the presence of CYP3A5*3, CYP3A5*6 and ABCB1 SNPs failed to confirm a significant association with the occurrence of vincristine-induced side effects
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17 [89] [90] [91] . These studies are limited due to the small number of patients included. In a recent abstract, investigators performed genome-wide SNP analysis in 321 pediatric ALL patients and demonstrated that variants of rs924607 localized to chromosome 5 within the promoter region of centrosomal protein of 72 kDa (CEP72), were linked to altered risks of vincristine-induced neuropathy [92] . Larger scale prospective studies, including a wider range of genotypic variants, are needed to address which SNPs best predict vincristine-induced neurotoxicity in ALL patients.
Tyrosine kinase inhibitor (TKI)
The Philadelphia chromosome (Ph) is the most common cytogenetic aberration in adult ALL. Translocation of genetic material between chromosomes 9 and 22
[t(9,22)(q34;q11)] produces a fusion gene BCR-ABL1, which result in a constitutively active tyrosine kinase [4] . Only 5% of children and those younger than 20
demonstrate Ph-chromosome positive ALL; but, the incidence increases to 33% in patients 20-40 years, 49% in those over 40 years and decreases to 35% in those over 60 years [4, 93, 94] . Combining the BCR-ABL1 inhibitor, imatinib, with conventional chemotherapy has increased the complete remission (CR) rate in these patients to 95%, and improved 3-year overall survival (OS) rate to >50%. Fielding et al. demonstrated that the inclusion of imatinib resulted in a significant improvement in long-term outcomes using a large database of clinical trials for Ph-positive ALL conducted prior to and after the development of imatinib therapy in the United Kingdom [95] . The 4-year OS was 38% in the imatinib cohort as compared with 22% in the A C C E P T E D M A N U S C R I P T
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18 chemotherapy only cohort [95] . Despite these results, Ph+ ALL patients exhibit heterogeneous responses to TKIs. This has been attributed to the presence of additional genetic abnormalities, for example, the Ikaros family zinic finger protein 1 (IKZF1) gene deletion [96] , novel BCR-ABL1 gene mutations, or disruption of drug transportation [4] .
Patients have also demonstrated wide inter-individual variability in the metabolism of imatinib which is mediated by CYP3A4/5 [97] . Although a number of polymorphisms in genes affecting drug transport and DNA repair have been associated with drug efficacy [98, 99] , pharmacogenetic studies of toxicity are rare. While patients with the TT genotype of ABCB1 gene loci 1236, 2677 and 3435 demonstrated higher drug clearance rate, individuals without these SNPs also did not demonstrate any significant toxicity related to higher drug levels [100] . Several reports have shown that CYP2D6*4 [101] or ABCG2421A variant alleles [102] may contribute to increased adverse effects. However, these data are not convincing enough to be conclusive, and most of the studies were performed in patients with chronic myeloid leukemia (CML) or gastrointestinal stromal tumors, not Ph+ ALL. It is important to note that, in contrast to CML, responses to imatinib in patients with Ph+ ALL are generally short-lived with high rates of relapse. When they do so, many of leukemia cells demonstrate novel point mutations in the BCR-ABL1 kinase or adjacent domain rendering them resistance to imatinib therapy [4, 103] . Although second-generation BCR-ABL1 TKIs, such as dasatinib and nilotinib, appear to be safe and efficacious in
imatinib resistant ALL patients, the emergence of T315I and other resistance conferring BCR-ABL1 mutations, lead to treatment failure [104] . More research is needed in order to better personalize TKI management in the treatment of Ph+ ALL.
Perspectives
Substantial changes have occurred in ALL therapy over the last several decades, with significant improvements in prognosis for patients with adult ALL. These successes are partially based on the progress in genetics and the incorporation of pharmacogenomics. New risk stratification, personalized regimens and therapeutic modification based upon insights into drug clearance ideally should be integrated with SNP genotypes and genetics testing to help us better predict therapy response and avoid drug toxicity. The FDA currently recommends genetic testing of TPMT for all patients who will be treated with high dose 6-MP in order to prevent hematopoietic toxicity. Despite these recommendations, the use of genetic testing to best individualize therapy is not universal. Among the barriers responsible for a failure to adopt such testing are inadequate recognition of the clinical benefits for patient care, high cost, concerns about the ethical implication of these data, and the technical challenges/availability of the tests. Additionally, pharmacogenomics alone will likely be insufficient to explain all of the variability. There may be some nihilism about the potential benefits of such testing. The application of pharmacogenomics remains a challenge; however these data support the proposition that this area warrants further research. We anticipate that in the future molecular profiles will help tailor A C C E P T E D M A N U S C R I P T
